Michael Gelband’s Merck MRK Stock Holding History

Michael Gelband’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000,000	Closed	-$83.9M	–	1869
2025 Q3	$83.9M	Buy	1,000,000 +750,000	+300%	+$61.8M	0.86%	10
2025 Q2	$19.8M	Buy	+250,000	New	+$19.9M	0.17%	113

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Michael Gelband's MRK Position: Q2 2026 in Review

Michael Gelband sold out of Merck (MRK) in Q2 2026, closing a stake of 144,655 shares — an estimated $17.4M sold.

Michael Gelband first reported a position in MRK in Q2 2019 and held it in 22 quarters. The position peaked at $63.6M in Q3 2023. 3,820 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Michael Gelband reported no remaining Merck position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 144,655 Merck shares in Q2 2026, an estimated $17.4M.
Michael Gelband first reported a position in Merck in Q2 2019 and held it in 22 quarters.
Michael Gelband's Merck position peaked at $63.6M in Q3 2023.
3,820 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.